Wall Street brokerages forecast that Supernus Pharmaceuticals (NASDAQ:SUPN) will announce earnings of $0.46 per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Supernus Pharmaceuticals’ earnings. The lowest EPS estimate is $0.42 and the highest is $0.50. Supernus Pharmaceuticals reported earnings per share of $0.32 in the same quarter last year, which would suggest a positive year over year growth rate of 43.8%. The business is expected to issue its next earnings report on Wednesday, August 1st.
On average, analysts expect that Supernus Pharmaceuticals will report full-year earnings of $1.91 per share for the current fiscal year, with EPS estimates ranging from $1.85 to $2.00. For the next year, analysts expect that the company will post earnings of $2.65 per share, with EPS estimates ranging from $2.22 to $3.05. Zacks’ EPS averages are a mean average based on a survey of analysts that cover Supernus Pharmaceuticals.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.26 by $0.18. The business had revenue of $88.44 million during the quarter, compared to the consensus estimate of $87.84 million. Supernus Pharmaceuticals had a net margin of 21.89% and a return on equity of 30.18%.
SUPN has been the subject of several research analyst reports. BidaskClub downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, January 26th. Berenberg Bank initiated coverage on shares of Supernus Pharmaceuticals in a report on Thursday, February 1st. They set a “buy” rating and a $66.00 target price for the company. ValuEngine raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Finally, Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Saturday, May 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $51.36.
In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 67,132 shares of the business’s stock in a transaction dated Friday, May 11th. The shares were sold at an average price of $53.11, for a total value of $3,565,380.52. Following the completion of the sale, the vice president now owns 32,500 shares of the company’s stock, valued at approximately $1,726,075. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Padmanabh P. Bhatt sold 7,868 shares of the business’s stock in a transaction dated Tuesday, May 15th. The shares were sold at an average price of $57.93, for a total transaction of $455,793.24. Following the completion of the sale, the vice president now directly owns 7,868 shares of the company’s stock, valued at approximately $455,793.24. The disclosure for this sale can be found here. Insiders sold a total of 152,850 shares of company stock valued at $7,596,524 in the last three months. Insiders own 6.20% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of SUPN. Public Employees Retirement Association of Colorado bought a new stake in Supernus Pharmaceuticals in the 4th quarter valued at about $188,000. Elkfork Partners LLC bought a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $217,000. Sigma Planning Corp bought a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $219,000. Wesbanco Bank Inc. bought a new stake in shares of Supernus Pharmaceuticals during the 1st quarter worth approximately $229,000. Finally, Parametrica Management Ltd bought a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $247,000. 97.29% of the stock is owned by hedge funds and other institutional investors.
Shares of SUPN stock traded up $0.40 during midday trading on Friday, hitting $54.95. 37,149 shares of the company were exchanged, compared to its average volume of 908,313. The company has a market capitalization of $2.85 billion, a price-to-earnings ratio of 43.61 and a beta of 1.14. The company has a debt-to-equity ratio of 0.90, a quick ratio of 4.74 and a current ratio of 4.90. Supernus Pharmaceuticals has a 52 week low of $33.30 and a 52 week high of $59.05.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.